Clinical Outcomes After Implantation of Overlapping Bioresorbable Scaffolds vs New Generation Everolimus Eluting Stents.
OBJECTIVE
There is limited evidence on procedural and clinical outcomes in patients treated with overlapping bioresorbable scaffolds vs overlapping everolimus-eluting stents. We evaluated the outcomes of propensity-matched patients treated with overlapping scaffolds vs everolimus-eluting stents.


METHODS
After propensity matching, 70 consecutive stable angina patients treated with overlapping bioresorbable scaffolds and 70 patients treated with overlapping new generation everolimus stents were included in this study. The primary outcome was the 1-year rate of major adverse cardiovascular events, defined as the composite of all-cause mortality, nonprocedural myocardial infarction, and target-vessel revascularization.


RESULTS
Patients in the 2 groups had similar age (scaffold vs stent: 64.5 ± 10.3 vs 66 ± 9.7 years; P=.381), sex, diabetes, previous cardiovascular history, and SYNTAX score (scaffold vs stent: 18.6 ± 9.2 vs 19.4 ± 10.4; P=.635). Postprocedural acute gain was significantly lower in patients treated with scaffolds (1.82±0.66 vs 2.03±0.68mm; P=.033). At 1-year follow up, the estimated major adverse cardiovascular event rate was not significantly different between the 2 groups (scaffold vs stent: 14.5% vs 14.6%; Plog-rank=.661). Similarly, no significant differences were seen in 1-year rates of target vessel (scaffold vs stent: 14.5% vs 10%; Plog-rank=.816) or target lesion revascularization (scaffold vs stent: 9.7% vs 8.3%; Plog-rank=.815).


CONCLUSIONS
Treating long lesions with overlapping scaffolds is feasible with acceptable 1-year outcomes.
Cardiovascular Sciences, Faculty of Medicine, National Heart and Lung Institute, Imperial College London, London, Greater London, United Kingdom; EMO-GVM Centro Cuore Columbus, Milan, Italy; Interventional Cardiology Department, San Raffaele Scientific Institute, Milan, Italy.
Vasileios F
VF
Panoulas
EMO-GVM Centro Cuore Columbus, Milan, Italy; Interventional Cardiology Department, San Raffaele Scientific Institute, Milan, Italy; Interventional Cardiology Unit, New Tokyo Hospital, Chiba, Japan.
Hiroyoshi
H
Kawamoto
EMO-GVM Centro Cuore Columbus, Milan, Italy; Interventional Cardiology Department, San Raffaele Scientific Institute, Milan, Italy.
Katsumasa
K
Sato
EMO-GVM Centro Cuore Columbus, Milan, Italy; Interventional Cardiology Department, San Raffaele Scientific Institute, Milan, Italy.
Tadashi
T
Miyazaki
EMO-GVM Centro Cuore Columbus, Milan, Italy; Interventional Cardiology Department, San Raffaele Scientific Institute, Milan, Italy; Interventional Cardiology Unit, New Tokyo Hospital, Chiba, Japan.
Toru
T
Naganuma
Interventional Cardiology Department, San Raffaele Scientific Institute, Milan, Italy.
Alessandro
A
Sticchi
EMO-GVM Centro Cuore Columbus, Milan, Italy; Interventional Cardiology Department, San Raffaele Scientific Institute, Milan, Italy.
Azeem
A
Latib
EMO-GVM Centro Cuore Columbus, Milan, Italy; Interventional Cardiology Department, San Raffaele Scientific Institute, Milan, Italy. Electronic address: info@emocolumbus.it.
Antonio
A
Colombo
D020341:Absorbable Implants; D000368:Aged; D060050:Angina, Stable / Q000601:surgery*; D000970:Antineoplastic Agents; D019917:Blood Vessel Prosthesis Implantation; D054855:Drug-Eluting Stents; D000068338:Everolimus; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention; D057216:Propensity Score; D012189:Retrospective Studies; D054457:Tissue Scaffolds; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D000068338:Everolimus
Armazón bioabsorbible; Bioresorbable scaffold; Drug eluting stent; Everolimus-eluting stent; Overlap; Solapamiento; Stent farmacoactivo; Stent liberador de everolimus; Strut